Using leucine to reverse muscle loss in cirrhosis
Official title: Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Run by The Cleveland Clinic · NCT03208868 · Data updated 2026-11-12
This study is testing if a special mixture of amino acids, including leucine, can help people with cirrhosis regain lost muscle and improve their strength.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 32 (estimated) |
| Sponsor | The Cleveland Clinic Academic / other |
| Locations | 1 site (Cleveland, Ohio) |
| Status | Recruiting |
| Started | August 5, 2013 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2028 |
| Registry record updated | August 21, 2026 |
| Trial ID | NCT03208868 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are cirrhotic patients with a Child's Pugh score of 5-9 who have abstained from alcohol and recreational drugs for at least six months.
✕Probably not a fit
Patients with a Child's score greater than 9, concurrent serious illnesses, or those on medications affecting muscle mass may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the use of a leucine enriched essential amino acid mixture to combat sarcopenia, a common complication in patients with cirrhosis. The researchers hypothesize that leucine can stimulate mTOR signaling, which may enhance protein synthesis and reduce muscle loss. By administering this amino acid mixture, the study aims to quantify changes in skeletal muscle mass in cirrhotic patients. The approach is based on preliminary findings suggesting that impaired mTOR signaling contributes to muscle loss in these patients.
Why it matters
Potential benefit: If successful, this treatment could significantly improve muscle mass and overall health in patients with cirrhosis.
How similar studies have gone: While the approach is based on preliminary studies, there is limited evidence from similar studies, making this a novel investigation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Cirrhotic patients: * Cirrhosis diagnosed by liver biopsy and/or clinical, biochemical and imaging evidence of cirrhosis. * Abstinence from alcohol and/or other recreational drugs for at least 6 months * Child's Pugh score 5-9 (inclusive). Exclusion * Cirrhotic patients: * Child's score \>9 * Pedal edema above the ankle * Presence of concurrent illnesses (renal, cardiac, pulmonary, cerebrovascular, malignancy) or medication (anabolic steroids, corticosteroids) intake that affect skeletal muscle mass. * Diabetes mellitus * Active gastrointestinal bleeding * Sepsis, encephalopathy * Renal failure * Hepatocellular carcinoma outside of Milan criteria * Unwilling to sign informed consent or follow research procedures * Does not meet inclusion criteria
Where it's running
-
Cleveland Clinic Foundation
Cleveland, Ohio, United States Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Bile acid and gut microbiota changes in people with hepatitis D starting bulevirtide
This project will see if starting bulevirtide changes bile acids and gut bacteria in adults with chronic hepatitis D who are already on hepatitis B therapy.
-
Diagnosing lymphohistiocytic hemophagocytosis in intensive care patients with liver disease
This study will test whether the HScore can accurately detect lymphohistiocytic hemophagocytosis in adults with hepatocellular insufficiency or cirrhosis admitted to intensive care.
-
Echocardiography-guided intensive care for septic shock in people with cirrhosis
This study will try using bedside ultrasound (POCUS) to guide fluid and blood-pressure treatment in adults with cirrhosis who develop sepsis-related low blood pressure.
-
Understanding social and health needs of people with chronic liver disease in outpatient care
This project will see how common social needs are and whether adults with chronic liver disease want their outpatient providers to help with them.
-
Non-invasive blood and imaging tests for metabolic liver disease
This project tests whether blood tests and imaging scans can diagnose and stage metabolic-associated steatohepatitis (MASH) and liver fibrosis in adults with metabolic risk factors.
-
High-protein, plant-dominant diet for people with liver cirrhosis
This 6-month test compares a high-protein, mostly plant-based diet to a usual low-fat animal-protein diet in adults with decompensated cirrhosis who are awaiting kidney transplant to see which better preserves nutrition and muscle.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.